Free Trial

Supernus Pharmaceuticals (SUPN) Earnings Date, Estimates & Call Transcripts

Supernus Pharmaceuticals logo
$49.19 +0.56 (+1.15%)
As of 05/5/2026 04:00 PM Eastern

Supernus Pharmaceuticals Earnings Summary

Supernus Pharmaceuticals posted Q3 2025 earnings on November 4, 2025, reporting an EPS of $0.46, which missed analysts' consensus estimates of $0.82 by $0.36. Quarterly revenue rose 9.3% year-over-year to $170 million, below the consensus estimate of $175.82 million. With a trailing EPS of -$0.68, Supernus Pharmaceuticals' earnings are expected to grow 105.62% next year, from $1.78 to $3.66 per share.

Latest Q3
Earnings Date
Nov. 4Estimated
Consensus EPS
(Nov. 4)
$0.82
Actual EPS
(Nov. 4)
$0.46 Missed By -$0.36
Actual Revenue
(Nov. 4)
$170.00M

Q3 2025 Earnings Resources

Get Supernus Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Supernus Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

SUPN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SUPN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Supernus Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate
$1.78 EPS
Next Year EPS Consensus Estimate
$3.66 EPS

Supernus Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025$0.82$0.46 -$0.36-$0.80$175.82M$170.00M
5/6/2025Q1 2025$0.26$0.28+$0.02-$0.21$145.59M$149.82M
11/4/2024Q3 2024$0.44$0.69+$0.25$1.21$157.35M$175.70M
8/6/2024Q2 2024$0.39$0.36 -$0.03$0.36$148.83M$168.30M

Data powered by Fiscal.ai.

Supernus Pharmaceuticals Earnings - Frequently Asked Questions

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earning data on Tuesday, November 4, 2025. Learn more on SUPN's earnings history.

Supernus Pharmaceuticals updated its FY 2026 earnings guidance on Tuesday, May, 5th. The company issued revenue guidance of $840.0 million-$870.0 million, compared to the consensus revenue estimate of $861.7 million.

In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) missed the analysts' consensus estimate of $0.82 by $0.36 with a reported earnings per share (EPS) of $0.46. Learn more on analysts' earnings estimate vs. SUPN's actual earnings.

The conference call for Supernus Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Supernus Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Supernus Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $718.95 million.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of -$38.55 million. SUPN has generated -$0.68 earnings per share over the last four quarters.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a forward price-to-earnings ratio of 27.63. The price/earnings-to-growth ratio is 0.96.

Supernus Pharmaceuticals' earnings are expected to grow from $1.78 per share to $3.66 per share in the next year, which is a 105.62% increase.


This page (NASDAQ:SUPN) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners